You are here

COVID-19

Alnylam sticks with aggressive litigation strategy against Pfizer and Moderna, filing yet another patent lawsuit

Alnylam sticks with aggressive litigation strategy against Pfizer and Moderna, filing yet another patent lawsuit

Fierce Pharma

Alnylam Pharmaceuticals

Moderna Therapeutics

Flag link:

EMA Panel Endorses Novavax's (NVAX) COVID vaccine for Full Approval

EMA Panel Endorses Novavax's (NVAX) COVID vaccine for Full Approval

Yahoo/Zacks.com

Flag link:

More Layoffs Signal COVID-19 Testing Boom Is Over

More Layoffs Signal COVID-19 Testing Boom Is Over

Medical Devices and Diagnostics Industry

Flag link:

FDA grants full approval to Pfizer Covid treatment Paxlovid for high-risk adults

FDA grants full approval to Pfizer Covid treatment Paxlovid for high-risk adults

CNBC

Flag link:

Orthopedic markets to return to normal this year as post-pandemic boost fades: analysts

Orthopedic markets to return to normal this year as post-pandemic boost fades: analysts

Medtech Dive

Flag link:

Concentra rebounds from Jounce buy with a shot at COVID-19-focused Atea

Concentra rebounds from Jounce buy with a shot at COVID-19-focused Atea

Fierce Biotech

Concerta Biosciences

Atea Pharmaceuticals

Flag link:

CureVac’s COVID vaccine patent battle with Pfizer, BioNTech heads South

CureVac’s COVID vaccine patent battle with Pfizer, BioNTech heads South

Medical Marketing and Media

Flag link:

Novavax employs AI-based dose selection for Covid-influenza vaccine trials

Novavax employs AI-based dose selection for Covid-influenza vaccine trials

Clinical Trials Arena

clinical trials

artificial intelligence

COVID-flu vaccines

Flag link:

The pandemic-era rule that lets you get telehealth prescriptions just got extended

The pandemic-era rule that lets you get telehealth prescriptions just got extended

NPR

Flag link:

The COVID public health emergency ends this week. Here's what's changing

The COVID public health emergency ends this week. Here's what's changing

NPR

Flag link:

Novavax cuts headcount by 25%, hitting hundreds of jobs, to align costs with dwindling COVID-19 market

Novavax cuts headcount by 25%, hitting hundreds of jobs, to align costs with dwindling COVID-19 market

Fierce Biotech

Flag link:

Layoffs Strike Thermo Fisher as COVID-19 Testing Demand Wanes

Layoffs Strike Thermo Fisher as COVID-19 Testing Demand Wanes

Medical Devices and Diagnostics Industry

Thermo Fisher Scientific

Flag link:

Cash-rich BioNTech broadens scope as COVID shot sales slide

Cash-rich BioNTech broadens scope as COVID shot sales slide

Yahoo/Reuters

Flag link:

Poland takes its COVID-19 vaccine fight to Pfizer's shareholders, urging the company to be a good corporate citizen

Poland takes its COVID-19 vaccine fight to Pfizer's shareholders, urging the company to be a good corporate citizen

Fierce Pharma

Flag link:

Pfizer reports strong Q1 earnings, including $18.3B in revenues

Pfizer reports strong Q1 earnings, including $18.3B in revenues

Medical Marketing and Media

Flag link:

One-third of US nurses plan to quit profession - report

One-third of US nurses plan to quit profession - report

Reuters

Flag link:

Second judge says US not liable in Moderna COVID-19 vaccine patent case

Second judge says US not liable in Moderna COVID-19 vaccine patent case

Reuters

Moderna Therapeutics

intellectual property

Flag link:

As federal emergency declaration expires, the picture of the pandemic grows fuzzier

As federal emergency declaration expires, the picture of the pandemic grows fuzzier

Medical Marketing and Media

Flag link:

Is Moderna Setting Expectations Too High?

Is Moderna Setting Expectations Too High?

Motley Fool

Moderna Therapeutics

Flag link:

Where Will Moderna Be in 1 Year?

Where Will Moderna Be in 1 Year?

Motley Fool

Moderna Therapeutics

Flag link:

Pages